MedTrace Logo

RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry

NCT03516695 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2021-04-21

No results posted yet for this study

Summary

This study is a non-interventional, observational, prospective, and global participant data registry. The study will collect effectiveness and safety data from approximately 1000 participants with liver cancers treated with TheraSphere® in a real-life setting from multiple centers globally. The absorbed dose to tumor and normal tissue will be calculated using the Simplicit90Y™ software in the subgroup of hepatocellular carcinoma (HCC) participants.

Conditions

Interventions

DEVICE

TheraSphere®

Intra-arterial Yttrium-90 glass microspheres

Sponsors & Collaborators

  • Biocompatibles UK Ltd

    collaborator INDUSTRY

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Riccardo Lencioni, MD · University of Miami (previously known affiliation)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-23
Primary Completion
2018-12-12
Completion
2018-12-12

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03516695 on ClinicalTrials.gov